Who are Telbivudine, Lamivudine, Adefovir ,Enecavir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Baraclude tablets, Adefovir Dipivoxil Tablets, Besifovir dipivoxil, Placebo & Entecavir, Telbivudine treatment, blank Baraclude tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/telbivudine-lamivudine-adefovir-enecavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Telbivudine, Lamivudine, Adefovir ,Enecavir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Telbivudine, Lamivudine, Adefovir ,Enecavir (Telbivudine, Lamivudine, Adefovir ,Enecavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI). Area: Virology/Hepatology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) Hepatitis B virus reverse transcriptase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Telbivudine, Lamivudine, Adefovir ,Enecavir (Telbivudine, Lamivudine, Adefovir ,Enecavir) — Shao-quan Zhang. These nucleoside/nucleotide reverse transcriptase inhibitors block hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Telbivudine, Lamivudine, Adefovir ,Enecavir TARGET	Telbivudine, Lamivudine, Adefovir ,Enecavir	Shao-quan Zhang	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI)	Hepatitis B virus reverse transcriptase
Baraclude tablets	Baraclude tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase
Adefovir Dipivoxil Tablets	Adefovir Dipivoxil Tablets	Sun Yat-sen University	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase and DNA polymerase
Besifovir dipivoxil	Besifovir dipivoxil	IlDong Pharmaceutical Co Ltd	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
Placebo & Entecavir	Placebo & Entecavir	Fu-Sheng Wang	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase
Telbivudine treatment	Telbivudine treatment	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
blank Baraclude tablets	blank Baraclude tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) class)

ANRS, Emerging Infectious Diseases · 1 drug in this class
Shao-quan Zhang · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Telbivudine, Lamivudine, Adefovir ,Enecavir — Competitive Intelligence Brief. https://druglandscape.com/ci/telbivudine-lamivudine-adefovir-enecavir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab